SCHEMBL4354599

SCHEMBL4354599

O=C(Nc1cc(Cl)ccc1O)NC1CCCCC1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.70
KMT2A Q03164 5/20 0.68
MEN1 O00255 4/20 0.68
CA12 O43570 1/20 0.64
CA1 P00915 1/20 0.64
CA9 Q16790 1/20 0.64
NPC1 O15118 6/20 0.62
EPHX1 P07099 5/20 0.62
SMN1; SMN2 Q16637 4/20 0.62
ALDH1A1 P00352 1/20 0.62
CYP2C9 P11712 1/20 0.62
CYP2C19 P33261 1/20 0.62
EPHX2 P34913 4/20 0.60
TSHR P16473 2/20 0.60
LMNA P02545 1/20 0.60
HTT P42858 1/20 0.59
POLB P06746 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2751414 0.85 RAB9A (0.78) RAB9AKMT2AMEN1NPC1EPHX1
SCHEMBL1463554 0.83 RAB9A (0.67) RAB9AKMT2AMEN1NPC1EPHX1
SCHEMBL4347651 0.83 MAPT (0.72) KMT2AMEN1NPC1SMN1; SMN2ALDH1A1
SCHEMBL2751842 0.83 RAB9A (0.70) RAB9AKMT2AMEN1NPC1EPHX1
SCHEMBL2751089 0.82 RAB9A (1.00) RAB9AKMT2AMEN1NPC1EPHX1
SCHEMBL12218290 0.81 KMT2A (1.00) RAB9AKMT2AMEN1NPC1EPHX1
SCHEMBL2750750 0.80 RAB9A (0.74) RAB9AKMT2AMEN1NPC1EPHX1
SCHEMBL4354309 0.80 RAB9A (0.66) RAB9AKMT2AMEN1NPC1EPHX1
SCHEMBL4345381 0.80 EPHX1 (0.63) RAB9AKMT2AMEN1NPC1EPHX1
SCHEMBL20365330 0.80 KMT2A (0.67) RAB9AKMT2AMEN1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
CN-100546977-C Suppress the new compound and the application thereof of rotamase JERINI AG (DE) 2009-10-07 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1402887-A1 New compounds for the inhibition of undesired cell proliferation and use thereof Jerini AG (DE) 2004-03-31 EP claimed
EP-1402888-A1 The use of substituted carbocyclic compounds as rotamases inhibitors Jerini AG (DE) 2004-03-31 EP claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 RAB9A 4228/4885KMT2A 2096/4885MEN1 2168/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 RAB9A 4588/4885KMT2A 1254/4885MEN1 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.